BACKGROUND: Systemic activation of hemostasis is frequently observed in cancer patients, even in the absence of thrombosis. Moreover, this activation has been implicated in tumor progression, angiogenesis and metastatic spread. Increased levels of D-dimer, which is a degradation product of cross-linked fibrin, indicate a global activation of hemostasis and fibrinolysis. DESIGN AND METHODS: In a prospective and observational cohort study, we assessed the prognostic value of D-dimer levels for overall survival and mortality risk in 1178 cancer patients included in the Vienna Cancer and Thrombosis Study (CATS). Patients were followed over 2 years at regular intervals until occurrence of symptomatic venous thromboembolism or death. D-dimer levels were measured with a quantitative D-dimer latex agglutination assay RESULTS: The main solid tumors were malignancies of the lung (n=182), breast (n=157), lower gastrointestinal tract (n=133), pancreas (n=74), stomach (n=50), kidney (n=37), prostate (n=133), and brain (n=148); 201 of the patients had hematologic malignancies; 63 had other tumors. During a median follow-up of 731 days, 460 (39.0%) patients died. The overall survival probabilities for patients with D-dimer levels categorized into four groups based on the 1(st), 2(nd) and 3(rd) quartiles of the D-dimer distribution in the total study population were 88%, 82%, 66% and 53% after 1 year, and 78%, 66%, 50% and 30% after 2 years, respectively (P<0.001). The univariate hazard ratio of D-dimer (per double increase) for mortality was 1.5 (95% confidence interval: 1.4-1.6, P<0.001) and remained increased in multivariable analysis including tumor subgroups, age, sex and venous thromboembolism. CONCLUSIONS: High D-dimer levels were associated with poor overall survival and increased mortality risk in cancer patients.
BACKGROUND: Systemic activation of hemostasis is frequently observed in cancerpatients, even in the absence of thrombosis. Moreover, this activation has been implicated in tumor progression, angiogenesis and metastatic spread. Increased levels of D-dimer, which is a degradation product of cross-linked fibrin, indicate a global activation of hemostasis and fibrinolysis. DESIGN AND METHODS: In a prospective and observational cohort study, we assessed the prognostic value of D-dimer levels for overall survival and mortality risk in 1178 cancerpatients included in the Vienna Cancer and Thrombosis Study (CATS). Patients were followed over 2 years at regular intervals until occurrence of symptomatic venous thromboembolism or death. D-dimer levels were measured with a quantitative D-dimer latex agglutination assay RESULTS: The main solid tumors were malignancies of the lung (n=182), breast (n=157), lower gastrointestinal tract (n=133), pancreas (n=74), stomach (n=50), kidney (n=37), prostate (n=133), and brain (n=148); 201 of the patients had hematologic malignancies; 63 had other tumors. During a median follow-up of 731 days, 460 (39.0%) patients died. The overall survival probabilities for patients with D-dimer levels categorized into four groups based on the 1(st), 2(nd) and 3(rd) quartiles of the D-dimer distribution in the total study population were 88%, 82%, 66% and 53% after 1 year, and 78%, 66%, 50% and 30% after 2 years, respectively (P<0.001). The univariate hazard ratio of D-dimer (per double increase) for mortality was 1.5 (95% confidence interval: 1.4-1.6, P<0.001) and remained increased in multivariable analysis including tumor subgroups, age, sex and venous thromboembolism. CONCLUSIONS: High D-dimer levels were associated with poor overall survival and increased mortality risk in cancerpatients.
Authors: K Blackwell; Z Haroon; G Broadwater; D Berry; L Harris; J D Iglehart; M Dewhirst; C Greenberg Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: F Dentali; W Ageno; M Giorgi Pierfranceschi; M G Pierfranceschi; D Imberti; A Malato; C Nitti; A Salvi; S Siragusa; A Squizzato; J Vitale; G Agnelli Journal: J Thromb Haemost Date: 2011-05 Impact factor: 5.824
Authors: R L Edwards; F R Rickles; T E Moritz; W G Henderson; L R Zacharski; W B Forman; C J Cornell; R J Forcier; J F O'Donnell; E Headley Journal: Am J Clin Pathol Date: 1987-11 Impact factor: 2.493
Authors: Kimberly Blackwell; Herbert Hurwitz; Grazyna Liebérman; William Novotny; Stacey Snyder; Mark Dewhirst; Charles Greenberg Journal: Cancer Date: 2004-07-01 Impact factor: 6.860
Authors: Eric Camerer; Aisha A Qazi; Daniel N Duong; Ivo Cornelissen; Rommel Advincula; Shaun R Coughlin Journal: Blood Date: 2004-03-18 Impact factor: 22.113
Authors: Luc Y Dirix; R Salgado; R Weytjens; C Colpaert; I Benoy; P Huget; P van Dam; A Prové; J Lemmens; P Vermeulen Journal: Br J Cancer Date: 2002-02-01 Impact factor: 7.640
Authors: Ingrid Pabinger; Nick van Es; Georg Heinze; Florian Posch; Julia Riedl; Eva-Maria Reitter; Marcello Di Nisio; Gabriela Cesarman-Maus; Noémie Kraaijpoel; Christoph Carl Zielinski; Harry Roger Büller; Cihan Ay Journal: Lancet Haematol Date: 2018-06-07 Impact factor: 18.959
Authors: Adam Durczynski; Anna Kumor; Piotr Hogendorf; Dariusz Szymanski; Piotr Grzelak; Janusz Strzelczyk Journal: World J Gastroenterol Date: 2014-09-28 Impact factor: 5.742